Analysis Group Health Care Consultants Present at 2012 ISPOR Conference
May 21, 2012
A contingent of Analysis Group consultants will moderate two podium sessions, present three podiums presentations, and exhibit 35 posters at the 17th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The theme of the conference, to be held June 2 to June 6 in Washington, D.C., is “Improving Health Care Efficiency.”
Podium Sessions:
Managing Principal Mei Sheng Duh will serve as moderator of a session titled “Comparative Effectiveness Research and Health Care.” In another session, Principal Howard Birnbaum will moderate presentations on “Health-Related Productivity.”
Podium Presentations:
Managing Principal Mei Sheng Duh will present “Incremental Clinical and Economic Burden of Uncontrolled Partial-Onset Seizures in a Privately Insured Population.” Manager Jasmina Ivanova and colleagues will discuss the “Association of Allergic Rhinitis with Asthma Exacerbations and Health Care Costs in Asthma Patients.” In another session, Manager James Signorovitch and colleagues will address “Comparative Efficacy at 48 Weeks of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Treatment of Naïve HIV-1 Patients: A Matching Adjusted Indirect Comparison of Randomized Trials.”
Posters:
Over the course of three days, members of our Health Care Consulting practice will present 35 posters focused on dosing and treatment patterns, health care utilization, and workplace productivity loss, and a range of diseases, including kidney disease, asthma, ADHD, cancer, lupus, diabetes, Parkinson’s Disease, and schizophrenia.
China Research:
Also included in the poster sessions is a series of studies on chronic diseases – including lung cancer, hepatocellular carcinoma, COPD, and Type 2 diabetes – led by Managing Principal Eric Wu that utilize Chinese health care data (e.g., claims data and surveys). The research team examined these diseases in terms of economic burden, treatment patterns, and patient-reported outcomes of patients in China. These studies are part of Analysis Group’s ongoing work with academics and partners in China to improve the quality and availability of various Chinese health care data.